NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ABEO

Abeona Therapeutics Inc

Jul 02 • 04:00PM ET

5.87

Dollar change +0.30
Percentage change 5.39	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN QURE SRPT SGMO BLUE CLGN ADVM FATE VYGR NTLA

| Held by: VTI IWM VXF SURI IWO ITOT IWC RSSL IWN UWM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	11.43%	Shs Outstand	48.95M	Perf Week	-1.84%
Market Cap	300.29M	Forward P/E	41.93	EPS next Y	0.14	Insider Trans	-2.04%	Shs Float	45.31M	Perf Month	-6.53%
Enterprise Value	239.78M	PEG	-	EPS next Q	-0.38	Inst Own	59.25%	Short Float	14.26%	Perf Quarter	31.91%
Income	-44.19M	P/S	-	EPS this Y	66.99%	Inst Trans	-2.37%	Short Ratio	3.48	Perf Half Y	4.26%
Sales	0.00M	P/B	6.94	EPS next Y	127.36%	ROA	-50.73%	Short Interest	6.46M	Perf YTD	5.39%
Book/sh	0.85	P/C	3.55	EPS next 5Y	-	ROE	-271.78%	52W High	7.32 -19.85%	Perf Year	38.44%
Cash/sh	1.65	P/FCF	-	EPS past 3/5Y	58.40% 47.21%	ROIC	-78.05%	52W Low	3.93 49.26%	Perf 3Y	28.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.30% 4.93%	Perf 5Y	-92.01%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	72.26%	Oper. Margin	-	ATR (14)	0.33	Perf 10Y	-96.31%
Dividend Ex-Date	-	Quick Ratio	4.90	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	47.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.90	EPS Q/Q	79.10%	SMA20	-3.42%	Beta	1.53	Target Price	19.93
Payout	-	Debt/Eq	0.58	Sales Q/Q	-	SMA50	-1.93%	Rel Volume	0.74	Prev Close	5.57
Employees	136	LT Debt/Eq	0.37	Earnings	May 15 BMO	SMA200	1.76%	Avg Volume	1.85M	Price	5.87
IPO	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	32.96% -	Trades		Volume	1,379,286	Change	5.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
07:30AM	Loading…
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
04:59PM	Loading…
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
09:00AM	Loading…
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%
Jun-21-24 03:08AM	Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO) (GuruFocus.com)
Jun-03-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 07:30AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 03:01AM	Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
02:17AM	Q1 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%
07:43AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress (GlobeNewswire)
May-07-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-03-24 11:19AM	Abeona Therapeutics Prices $75 Million Securities Offering; Shares Rise (MT Newswires) +13.02%
07:30AM	Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Apr-23-24 02:04PM	Top Midday Decliners (MT Newswires) -53.67%
08:53AM	Why Is Abeona Therapeutics (ABEO) Stock Down 45% Today? (InvestorPlace)
07:39AM	Top Premarket Decliners (MT Newswires)
07:09AM	FDA rejects Abeona cell therapy, asks for more manufacturing data (BioPharma Dive)
Apr-22-24 05:58PM	Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval (MT Newswires)
04:27PM	UPDATE 1-US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:14PM	US FDA declines to approve Abeona's skin disorder treatment (Reuters)
04:05PM	Abeona Therapeutics Provides Regulatory Update on Pz-cel (GlobeNewswire)
Apr-01-24 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.48%
Mar-19-24 06:53AM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +8.30%
05:31AM	Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results (GuruFocus.com)
Mar-18-24 07:30AM	Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections (GlobeNewswire) -19.00%
Mar-05-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.32%
Feb-15-24 05:52AM	Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc (GuruFocus.com) +5.53%
Feb-01-24 04:05PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.65%
07:30AM	Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) (GlobeNewswire)
Jan-08-24 07:30AM	Abeona Therapeutics Announces $50 Million Credit Facility (GlobeNewswire)
Dec-15-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-23 07:30AM	Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) (GlobeNewswire) +11.60%
Nov-17-23 10:09AM	Abeona Therapeutics Inc. (NASDAQ:ABEO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 04:29AM	Q3 2023 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.56%
Nov-13-23 12:23PM	Abeona Therapeutics Inc (ABEO) Reports Q3 2023 Financial Results and Advances in Commercial ... (GuruFocus.com) +10.02%
07:41AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments (GlobeNewswire)
Nov-01-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 07:30AM	Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) +9.84%
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
07:30AM	Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer (GlobeNewswire)
Sep-07-23 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 07:30AM	Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission (GlobeNewswire) +5.60%
Aug-11-23 07:41AM	ABEO: On Track to File BLA in 3Q23... (Zacks)
Aug-08-23 08:27AM	Abeona Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Abeona Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 07:30AM	Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023 (GlobeNewswire) +5.37%

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vazzano Joseph Walter	Chief Financial Officer	Jun 06 '25	Sale	6.76	17,795	120,294	491,246	Jun 06 06:04 PM
Seshadri Vishwas	Chief Executive Officer	Jun 06 '25	Sale	6.76	50,676	342,570	1,303,761	Jun 06 06:00 PM
O'Malley Brendan M.	SVP, General Counsel	Jun 06 '25	Sale	6.76	10,470	70,777	378,245	Jun 06 05:56 PM
Vazzano Joseph Walter	Officer	Jun 06 '25	Proposed Sale	6.76	17,795	120,314		Jun 06 04:13 PM
O'Malley Brendan M.	Director	Jun 06 '25	Proposed Sale	6.76	10,470	70,789		Jun 06 04:12 PM
Seshadri Vishwas	Officer	Jun 06 '25	Proposed Sale	6.76	50,676	342,626		Jun 06 04:11 PM
Alvino Mark	Director	May 27 '25	Sale	6.38	2,000	12,760	90,435	May 27 07:57 PM
Alvino Mark	Director	May 27 '25	Proposed Sale	6.38	2,000	12,762		May 27 04:40 PM
Alvino Mark	Director	May 16 '25	Sale	5.68	8,000	45,440	92,435	May 16 05:23 PM
Alvino Mark	Director	May 16 '25	Proposed Sale	5.68	8,000	45,423		May 16 04:07 PM
Seshadri Vishwas	Chief Executive Officer	Mar 31 '25	Sale	4.78	25,000	119,500	1,355,322	Mar 31 07:17 PM
Seshadri Vishwas	Officer	Mar 31 '25	Proposed Sale	4.78	25,000	119,560		Mar 31 04:08 PM
Alvino Mark	Director	Jan 29 '25	Sale	5.38	4,000	21,520	64,334	Jan 31 04:30 PM
Alvino Mark	Officer	Jan 29 '25	Proposed Sale	5.41	4,000	21,640		Jan 29 04:03 PM
Alvino Mark	Director	Jan 21 '25	Sale	5.10	4,000	20,400	68,334	Jan 21 04:30 PM
Alvino Mark	Officer	Jan 21 '25	Proposed Sale	5.22	4,000	20,880		Jan 21 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABEO

Abeona Therapeutics Inc

Upgrade your FINVIZ experience